137 related articles for article (PubMed ID: 2662829)
1. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
[TBL] [Abstract][Full Text] [Related]
2. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
Arneklo-Nobin B; Elmér O; Akesson A
Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
[TBL] [Abstract][Full Text] [Related]
5. International study of ketanserin in Raynaud's phenomenon.
Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
[TBL] [Abstract][Full Text] [Related]
6. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
Engelhart M
Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
[TBL] [Abstract][Full Text] [Related]
7. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
Dormandy JA; Berent A; Downes SJ
Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
Seibold JR; Jageneau AH
Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
[TBL] [Abstract][Full Text] [Related]
9. Ketanserin and capillary flow in Raynaud's phenomenon.
Tooke JE; Williams SA; Rawlinson DW; Black C
Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
[TBL] [Abstract][Full Text] [Related]
10. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.
Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G
Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876
[TBL] [Abstract][Full Text] [Related]
11. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
[No Abstract] [Full Text] [Related]
12. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000954. PubMed ID: 10796396
[TBL] [Abstract][Full Text] [Related]
13. Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon.
Caputi CA; De Carolis G; Tomasetti C
Angiology; 1991 Jun; 42(6):473-80. PubMed ID: 2042796
[TBL] [Abstract][Full Text] [Related]
14. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.
Brouwer RM; Wenting GJ; Schalekamp MA
J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A
Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126
[TBL] [Abstract][Full Text] [Related]
16. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
[TBL] [Abstract][Full Text] [Related]
17. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
[TBL] [Abstract][Full Text] [Related]
18. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
[TBL] [Abstract][Full Text] [Related]
19. [Hemorheological, hemocoagulation and photoplethysmographic changes induced by the administration of pentoxifylline in patients with Raynaud's disease].
Macchione C; Molaschi M; Neirotti M; Garrone MT; Longo F; Pernigotti L
Minerva Med; 1985 Jul; 76(30-31):1401-5. PubMed ID: 4022431
[TBL] [Abstract][Full Text] [Related]
20. Functional vascular disorders: treatment with pentoxifylline.
Neirotti M; Longo F; Molaschi M; Macchione C; Pernigotti L
Angiology; 1987 Aug; 38(8):575-80. PubMed ID: 3631642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
